MPL approves sale of UK subsidiary Notedome to C.O.I.M.

Core Business DivestedStrategic Transactions View source PDF Explain this filing

MANALIPETC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹73.15

prior close

₹74.09

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+0.6% vs market

Petrochemicals peers, median of 12sector+0.8%+0.8% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.8 pts more than its Petrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.2

10m

+2.2

15m

+0.6

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+1.0+0.6+0.8+0.8

Next day

-0.8+1.5-2.4+0.7-1.6

-0.9+1.0-1.9+0.2-1.0

-3.6+2.0-5.6+0.5-4.1

-2.6+3.1-5.7+1.7-4.3

-2.8+2.6-5.4+1.2-4.0

+1.8+2.7-0.9+2.2-0.4

15d

-5.5+1.8-7.2-0.1-5.4

-6.9+2.5-9.4+1.2-8.1

-15.9-2.9-13.1-7.2-8.7

-19.8-6.3-13.5-14.8-4.9

UpDownMarket · Nifty Microcap 250Sector · Petrochemicals peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

MPL's board approved the sale of AMCHEM SG's entire stake in UK subsidiary Notedome to C.O.I.M. S.p.A., subject to shareholder approval. The share purchase agreement is yet to be signed. The cash-free, debt-free sale is priced at no less than 8.5 times adjusted EBITDA of GBP 2.12 million, with completion tentatively targeted by end-November 2025. Notedome contributed 10.63% of consolidated income and 5.57% of net worth in FY2024-25.

Likely market impact

The sale may unlock value and simplify MPL's overseas portfolio, but shareholder approval and deal completion remain pending, leaving the near-term stock impact uncertain.